Effect of smoking, hypertension and lifestyle factors on kidney cancer - perspectives for prevention and screening programmes.


Journal

Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082

Informations de publication

Date de publication:
Nov 2023
Historique:
accepted: 12 05 2023
medline: 3 11 2023
pubmed: 17 6 2023
entrez: 16 6 2023
Statut: ppublish

Résumé

Renal cell carcinoma (RCC) incidence has doubled over the past few decades. However, death rates have remained stable as the number of incidental renal mass diagnoses peaked. RCC has been recognized as a European health care issue, but to date, no screening programmes have been introduced. Well-known modifiable risk factors for RCC are smoking, obesity and hypertension. A direct association between cigarette consumption and increased RCC incidence and RCC-related death has been reported, but the underlying mechanistic pathways for this association are still unclear. Obesity is associated with an increased risk of RCC, but interestingly, improved survival outcomes have been reported in obese patients, a phenomenon known as the obesity paradox. Data on the association between other modifiable risk factors such as diet, dyslipidaemia and physical activity with RCC incidence are conflicting, and potential mechanisms underlying these associations remain to be elucidated.

Identifiants

pubmed: 37328546
doi: 10.1038/s41585-023-00781-8
pii: 10.1038/s41585-023-00781-8
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

669-681

Informations de copyright

© 2023. Springer Nature Limited.

Références

Cairns, P. Renal cell carcinoma. Cancer Biomark. 9, 461 (2011).
pmcid: 3308682 doi: 10.3233/CBM-2011-0176
Cimadamore, A. et al. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. Transl. Androl. Urol. 10, 1506–1520 (2021).
pubmed: 33850785 pmcid: 8039604 doi: 10.21037/tau-20-1150
Signoretti, S., Flaifel, A., Chen, Y. B. & Reuter, V. E. Renal cell carcinoma in the era of precision medicine: from molecular pathology to tissue-based biomarkers. J. Clin. Oncol. 36, 3553–3559 (2018).
pmcid: 6299340 doi: 10.1200/JCO.2018.79.2259
Ferlay, J. et al. Source: Globocan 2020. Globocan 419, 3–4 (2020).
Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941–1953 (2019).
pubmed: 30350310 doi: 10.1002/ijc.31937
American Cancer Society. Key Statistics About Kidney Cancer. American Cancer Society https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html (2023).
Capitanio, U. et al. Epidemiology of renal cell carcinoma [Figure presented]. Eur. Urol. 75, 74–84 (2019).
pubmed: 30243799 doi: 10.1016/j.eururo.2018.08.036
Huang, J. et al. A global trend analysis of kidney cancer incidence and mortality and their associations with smoking, alcohol consumption, and metabolic syndrome. Eur. Urol. Focus. 8, 200–209 (2022).
pubmed: 33495133 doi: 10.1016/j.euf.2020.12.020
Patel, H. D. et al. Clinical stage migration and survival for renal cell carcinoma in the United States. Eur. Urol. Oncol. 2, 343–348 (2019).
pubmed: 31277771 doi: 10.1016/j.euo.2018.08.023
Sanchez, A., Feldman, A. S. & Ari Hakimi, A. Current management of small renal masses, including patient selection, renal tumor biopsy, active surveillance, and thermal ablation. J. Clin. Oncol. 36, 3591–3600 (2018).
pubmed: 30372390 pmcid: 6804853 doi: 10.1200/JCO.2018.79.2341
Al-Bayati, O., Hasan, A., Pruthi, D., Kaushik, D. & Liss, M. A. Systematic review of modifiable risk factors for kidney cancer. Urol. Oncol. 37, 359–371 (2019).
pubmed: 30685335 doi: 10.1016/j.urolonc.2018.12.008
Ba, Z. et al. Risk factors for the comorbidity of hypertension and renal cell carcinoma in the cardio-oncologic era and treatment for tumor-induced hypertension. Front. Cardiovasc. Med. 9, 810262 (2022).
pubmed: 35252390 pmcid: 8892205 doi: 10.3389/fcvm.2022.810262
Rai, B. P. et al. Systematic review of the incidence of and risk factors for urothelial cancers and renal cell carcinoma among patients with haematuria. Eur. Urol. https://doi.org/10.1016/J.EURURO.2022.03.027 (2022).
doi: 10.1016/J.EURURO.2022.03.027 pubmed: 35393159
Chow, W. H., Dong, L. M. & Devesa, S. S. Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 7, 245–257 (2010).
pubmed: 20448658 pmcid: 3012455 doi: 10.1038/nrurol.2010.46
NCI. NCI Dictionary of Cancer Terms. NCI https://www.cancer.gov/publications/dictionaries/cancer-terms (2010).
Jacob, L., Freyn, M., Kalder, M., Dinas, K. & Kostev, K. Impact of tobacco smoking on the risk of developing 25 different cancers in the UK: a retrospective study of 422,010 patients followed for up to 30 years. Oncotarget 9, 17420–17429 (2018).
pubmed: 29707117 pmcid: 5915125 doi: 10.18632/oncotarget.24724
MacLeod, L. C. et al. Risk factors for renal cell carcinoma in the VITAL study. J. Urol. 190, 1657–1661 (2013).
pubmed: 23665301 pmcid: 4420476 doi: 10.1016/j.juro.2013.04.130
Mariusdottir, E. et al. Occupation as a risk factor for renal cell cancer: a nationwide, prospective epidemiological study. Scand. J. Urol. 50, 181–185 (2016).
pubmed: 26999634 doi: 10.3109/21681805.2016.1151460
Wang, G. et al. Risk factor for clear cell renal cell carcinoma in Chinese population: a case-control study. Cancer Epidemiol. 36, 177–182 (2012).
pubmed: 22000673 doi: 10.1016/j.canep.2011.09.006
National Cancer Institute. Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). NCI https://prevention.cancer.gov/major-programs/prostate-lung-colorectal-and-ovarian-cancer-screening-trial-plco (2010).
Lotan, Y. et al. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. Urol. Oncol. Semin. Orig. Investig. 34, 167.e9–167.e16 (2016).
Laaksonen, M. A. et al. The future burden of kidney and bladder cancers preventable by behavior modification in Australia: a pooled cohort study. Int. J. Cancer 146, 874–883 (2020).
pubmed: 31107541 doi: 10.1002/ijc.32420
Cumberbatch, M. G., Rota, M., Catto, J. W. F. & La Vecchia, C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur. Urol. 70, 458–466 (2016).
pubmed: 26149669 doi: 10.1016/j.eururo.2015.06.042
Hara, T. et al. Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association. Jpn. J. Clin. Oncol. 47, 1162–1169 (2017).
pubmed: 29121328 doi: 10.1093/jjco/hyx129
Ehdaie, B., Furberg, H., Zabor, E. C., Hakimi, A. A. & Russo, P. Comprehensive assessment of the impact of cigarette smoking on survival of clear cell kidney cancer. J. Urol. 191, 597–602 (2014).
pubmed: 24018238 doi: 10.1016/j.juro.2013.08.081
Al Hussein Al Awamlh, B. et al. Association of smoking and death from genitourinary malignancies: analysis of the National Longitudinal Mortality Study. J. Urol. 202, 1248–1254 (2019).
pubmed: 31290707 doi: 10.1097/JU.0000000000000433
Kroeger, N. et al. Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer 118, 1795–1802 (2012).
pubmed: 21997347 doi: 10.1002/cncr.26453
Li, Y. & Hecht, S. S. Carcinogenic components of tobacco and tobacco smoke: a 2022 update. Food Chem. Toxicol. 165, 113179 (2022).
pubmed: 35643228 pmcid: 9616535 doi: 10.1016/j.fct.2022.113179
Buendia Jimenez, I. et al. Effect of increased water intake on urinary DNA adduct levels and mutagenicity in smokers: a randomized study. Dis. Markers 2015, 478150 (2015).
Eckel-Passow, J. E. et al. ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma. BMC Urol. 14, 14 (2014).
pubmed: 24479813 pmcid: 3944917 doi: 10.1186/1471-2490-14-14
Lin, J. et al. Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk. Carcinogenesis 33, 1699–1706 (2012).
pubmed: 22665367 pmcid: 3514904 doi: 10.1093/carcin/bgs192
Zhang, R., Yip, V. L. Y. & Withers, S. G. Mechanisms of enzymatic glycosyl transfer. Compr. Nat. Prod. II Chem. Biol. 8, 385–422 (2010).
B, H., A, I., L, B. & B, I. Elevated urinary excretion of beta-hexosaminidase in smokers. Eur. J. Clin. Chem. Clin. Biochem. 30, 131–133 (1992).
Kim, L. H. et al. A Systematic review and meta-analysis of the significance of body mass index on kidney cancer outcomes. J. Urol. 205, 346–355 (2021).
pubmed: 32945696 doi: 10.1097/JU.0000000000001377
Wang, F. & Xu, Y. Body mass index and risk of renal cell cancer: a dose-response meta-analysis of published cohort studies. Int. J. Cancer 135, 1673–1686 (2014).
pubmed: 24615287 doi: 10.1002/ijc.28813
Choi, Y. et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int. J. Cancer 132, 625–634 (2013).
pubmed: 22610826 doi: 10.1002/ijc.27639
Song, X. et al. Body mass index and cancer incidence: the FINRISK study. Eur. J. Epidemiol. 29, 477–487 (2014).
pubmed: 24997743 doi: 10.1007/s10654-014-9934-z
Landberg, A., Fält, A., Montgomery, S., Sundqvist, P. & Fall, K. Overweight and obesity during adolescence increases the risk of renal cell carcinoma. Int. J. Cancer 145, 1232–1237 (2019).
pubmed: 30790271 pmcid: 6899622 doi: 10.1002/ijc.32147
Nam, G. E. et al. Obesity, abdominal obesity and subsequent risk of kidney cancer: a cohort study of 23.3 million East Asians. Br. J. Cancer 121, 271–277 (2019).
pubmed: 31231120 pmcid: 6738324 doi: 10.1038/s41416-019-0500-z
Lowrance, W. T. et al. Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int. 105, 16–20 (2010).
pubmed: 19583732 doi: 10.1111/j.1464-410X.2009.08706.x
Beebe-Dimmer, J. L. et al. Body mass index and renal cell cancer: the influence of race and sex. Epidemiology 23, 821–828 (2012).
pubmed: 23007040 pmcid: 3466395 doi: 10.1097/EDE.0b013e31826b7fe9
Brennan, P. et al. Tobacco smoking, body mass index, hypertension, and kidney cancer risk in central and eastern Europe. Br. J. Cancer 99, 1912–1915 (2008).
pubmed: 19034282 pmcid: 2600689 doi: 10.1038/sj.bjc.6604761
Shen, T. et al. Association of hypertension and obesity with renal cell carcinoma risk: a report from the Shanghai Men’s and Women’s Health Studies. Cancer Causes Control. 26, 1173–1180 (2015).
pubmed: 26081424 pmcid: 4500104 doi: 10.1007/s10552-015-0611-7
Tchernof, A. & Després, J. P. Pathophysiology of human visceral obesity: an update. Physiol. Rev. 93, 359–404 (2013).
pubmed: 23303913 doi: 10.1152/physrev.00033.2011
Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579–591 (2004).
pubmed: 15286738 doi: 10.1038/nrc1408
Waalkes, S. et al. Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control. 21, 1905–1910 (2010).
pubmed: 20652393 doi: 10.1007/s10552-010-9618-2
AJ, R. et al. Obesity is associated with an improved cancer-specific survival, but an increased rate of postoperative complications after surgery for renal cell carcinoma. Scand. J. Urol. Nephrol. 46, 348–357 (2012).
doi: 10.3109/00365599.2012.678382
Y, N. et al. Influence of visceral obesity on oncologic outcome in patients with renal cell carcinoma. Urol. Int. 85, 30–36 (2010).
doi: 10.1159/000318988
G, K. et al. Visceral obesity is associated with better recurrence-free survival after curative surgery for Japanese patients with localized clear cell renal cell carcinoma. Jpn. J. Clin. Oncol. 45, 210–216 (2015).
doi: 10.1093/jjco/hyu193
Sanchez, A. et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol. 21, 283–293 (2020).
pubmed: 31870811 doi: 10.1016/S1470-2045(19)30797-1
Mizuno, R. et al. Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy. Med. Oncol. 34, 47 (2017).
pubmed: 28213730 doi: 10.1007/s12032-017-0908-3
Lee, S. W. et al. Size and volumetric growth kinetics of renal masses in patients with renal cell carcinoma. Urology https://doi.org/10.1016/j.urology.2015.10.051 (2016).
doi: 10.1016/j.urology.2015.10.051 pubmed: 28034532 pmcid: 5112679
Albiges, L. et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J. Clin. Oncol. 34, 3655–3663 (2016).
pubmed: 27601543 pmcid: 5065111 doi: 10.1200/JCO.2016.66.7311
Lauby-Secretan, B. et al. Body fatness and cancer — Viewpoint of the IARC Working Group. N. Engl. J. Med. 375, 794–798 (2016).
pubmed: 27557308 pmcid: 6754861 doi: 10.1056/NEJMsr1606602
Balkwill, F. R., Capasso, M. & Hagemann, T. The tumor microenvironment at a glance. J. Cell Sci. 125, 5591–5596 (2012).
pubmed: 23420197 doi: 10.1242/jcs.116392
Yuan, Y. et al. Expression and prognostic significance of fatty acid synthase in clear cell renal cell carcinoma. Pathol. Res. Pract. 216, 153227 (2020).
pubmed: 33027752 doi: 10.1016/j.prp.2020.153227
Ito, R. et al. The impact of obesity and adiponectin signaling in patients with renal cell carcinoma: a potential mechanism for the ‘obesity paradox’. PLoS One 12, 1–22 (2017).
doi: 10.1371/journal.pone.0171615
Barazzoni, R. et al. Sarcopenic obesity: time to meet the challenge. Obes. Facts 11, 294–305 (2018).
pubmed: 30016792 pmcid: 6189532 doi: 10.1159/000490361
Christakoudi, S. et al. Blood pressure and risk of cancer in the European prospective investigation into cancer and nutrition. Int. J. Cancer 146, 2680–2693 (2020).
pubmed: 31319002 doi: 10.1002/ijc.32576
Schouten, L. J. et al. Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study. J. Hypertens. 23, 1997–2004 (2005).
pubmed: 16208141 doi: 10.1097/01.hjh.0000186023.74245.48
Fraser, G. E., Phillips, R. L. & Beeson, W. L. Hypertension, antihypertensive medication and risk of renal carcinoma in California seventh-day adventists. Int. J. Epidemiol. 19, 832–838 (1990).
pubmed: 2084009 doi: 10.1093/ije/19.4.832
Flaherty, K. T. et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control. 16, 1099–1106 (2005).
pubmed: 16184476 doi: 10.1007/s10552-005-0349-8
Setiawan, V. W., Stram, D. O., Nomura, A. M. Y., Kolonel, L. N. & Henderson, B. E. Risk factors for renal cell cancer: the multiethnic cohort. Am. J. Epidemiol. 166, 932–940 (2007).
pubmed: 17656615 doi: 10.1093/aje/kwm170
Washio, M. et al. Risk factors for renal cell carcinoma in a Japanese population. Asian Pac. J. Cancer Prev. 15, 9065–9070 (2014).
pubmed: 25422180 doi: 10.7314/APJCP.2014.15.21.9065
McLaughlin, J. K. et al. Risk factors for renal‐cell cancer in Shanghai, China. Int. J. Cancer 52, 562–565 (1992).
pubmed: 1399137 doi: 10.1002/ijc.2910520411
Hofmann, J. N. et al. Chronic kidney disease and risk of renal cell carcinoma: differences by race. Epidemiology 26, 59–67 (2015).
pubmed: 25393631 pmcid: 4422505 doi: 10.1097/EDE.0000000000000205
Grove, J. S., Nomura, A., Severson, R. K. & Stemmermann, G. N. The association of blood pressure with cancer incidence in a prospective study. Am. J. Epidemiol. 134, 942–947 (1991).
pubmed: 1951291 doi: 10.1093/oxfordjournals.aje.a116178
Chow, W.-H., Gridley, G., Fraumeni, J. F. & Järvholm, B. Obesity, hypertension, and the risk of kidney cancer in men. N. Engl. J. Med. 343, 1305–1311 (2000).
pubmed: 11058675 doi: 10.1056/NEJM200011023431804
Vatten, L. J., Trichopoulos, D., Holmen, J. & Nilsen, T. I. L. Blood pressure and renal cancer risk: the HUNT Study in Norway. Br. J. Cancer 97, 112–114 (2007).
pubmed: 17519895 pmcid: 2359653 doi: 10.1038/sj.bjc.6603823
Häggström, C. et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS One 8, e57475 (2013).
pubmed: 23468995 pmcid: 3585341 doi: 10.1371/journal.pone.0057475
Sanfilippo, K. M. et al. Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women. Hypertension 63, 934–941 (2014).
pubmed: 24637660 doi: 10.1161/HYPERTENSIONAHA.113.02953
Fryzek, J. P. et al. A cohort study of antihypertensive treatments and risk of renal cell cancer. Br. J. Cancer 92, 1302–1306 (2005).
pubmed: 15812478 pmcid: 2361985 doi: 10.1038/sj.bjc.6602490
Heaf, J. G., Hansen, A. & Laier, G. H. Hypertensive nephropathy is associated with an increased risk of myeloma, skin, and renal cancer. J. Clin. Hypertens. 21, 786–791 (2019).
doi: 10.1111/jch.13565
Karamzad, N., Ayubi, E., Rahmani, V. & Safiri, S. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer: methodological issues. World J. Urol. 35, 1467–1468 (2017).
pubmed: 27864618 doi: 10.1007/s00345-016-1974-4
McLaughlin, J. K. et al. International renal‐cell cancer study. VIII. Role of diuretics, other anti‐hypertensive medications and hypertension. Int. J. Cancer 63, 216–221 (1995).
pubmed: 7591207 doi: 10.1002/ijc.2910630212
Yuan, J. M., Castelao, J. E., Gago-Dominguez, M., Ross, R. K. & Yu, M. C. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br. J. Cancer 77, 1508–1513 (1998).
pubmed: 9652770 pmcid: 2150191 doi: 10.1038/bjc.1998.248
Colt, J. S. et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 22, 797–804 (2011).
pubmed: 21881515 pmcid: 3188386 doi: 10.1097/EDE.0b013e3182300720
McCredie, M. & Stewart, J. H. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control. 3, 323–331 (1992).
pubmed: 1617119 doi: 10.1007/BF00146885
Finkle, W. D., McLaughlin, J. K., Rasgon, S. A., Yeoh, H. H. & Low, J. E. Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control. 4, 555–558 (1993).
pubmed: 8280833 doi: 10.1007/BF00052431
Kreiger, N., Marrett, L. D., Dodds, L., Hilditch, S. & Darlington, G. A. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control. 4, 101–110 (1993).
pubmed: 8481488 doi: 10.1007/BF00053150
Hiatt, R. A., Tolan, K. & Quesenberry, C. P. Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). Cancer Causes Control. 5, 319–325 (1994).
pubmed: 8080943 doi: 10.1007/BF01804982
Weikert, S. et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am. J. Epidemiol. 167, 438–446 (2008).
pubmed: 18048375 doi: 10.1093/aje/kwm321
Kocher, N. J., Rjepaj, C., Robyak, H., Lehman, E. & Raman, J. D. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer. World J. Urol. 35, 67–72 (2017).
pubmed: 27189620 doi: 10.1007/s00345-016-1850-2
Shapiro, J. A. et al. Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am. J. Epidemiol. 149, 521–530 (1999).
pubmed: 10084241 doi: 10.1093/oxfordjournals.aje.a009848
Hidayat, K., Du, X., Zou, S. Y. & Shi, B. M. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J. Hypertens. 35, 1333–1344 (2017).
pubmed: 28157813 doi: 10.1097/HJH.0000000000001286
Seretis, A. et al. Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci. Rep. 9, 8565 (2019).
pubmed: 31189941 pmcid: 6561976 doi: 10.1038/s41598-019-45014-4
McLaughlin, J. K. et al. International renal‐cell cancer study. VIII. Role of diuretics, other anti‐hypertensive medications and hypertension. Int. J. Cancer 63, 216–221 (1995).
pubmed: 7591207 doi: 10.1002/ijc.2910630212
Colt, J. S. et al. Antihypertensive medication use and risk of renal cell carcinoma. Cancer Causes Control. 28, 289–297 (2017).
pubmed: 28224412 pmcid: 6417807 doi: 10.1007/s10552-017-0857-3
Liu, Y. et al. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. BMC Urol. 19, 49 (2019).
pubmed: 31174518 pmcid: 6555944 doi: 10.1186/s12894-019-0481-5
Suyama, T. et al. Impact of hypertension on recurrence and survival of patients with renal cell carcinoma after surgery. J. Clin. Oncol. 36, 611–611 (2018).
doi: 10.1200/JCO.2018.36.6_suppl.611
Chow, W. H. et al. Risk of renal cell cancer in relation to diuretics, antihypertensive drugs, and hypertension. Cancer Epidemiol. Biomark. Prev. 4, 327–331 (1995).
Heath, C. W., Lally, C. A., Calle, E. E., McLaughlin, J. K. & Thun, M. J. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am. J. Epidemiol. 145, 607–613 (1997).
pubmed: 9098177 doi: 10.1093/oxfordjournals.aje.a009157
Graff, R. E. et al. Type 2 diabetes in relation to the risk of renal cell carcinoma among men and women in two large prospective cohort studies. Diabetes Care 41, 1432–1437 (2018).
pubmed: 29678810 pmcid: 6014546 doi: 10.2337/dc17-2518
Sawada, N. et al. Body mass index and subsequent risk of kidney cancer: a prospective cohort study in Japan. Ann. Epidemiol. 20, 466–472 (2010).
pubmed: 20470974 doi: 10.1016/j.annepidem.2010.03.008
Dankner, R. et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am. J. Epidemiol. 183, 1098–1106 (2016).
pubmed: 27257115 doi: 10.1093/aje/kwv290
Habib, S. L., Prihoda, T. J., Luna, M. & Werner, S. A. Diabetes and risk of renal cell carcinoma. J. Cancer 3, 42–48 (2012).
pubmed: 22232697 doi: 10.7150/jca.3718
Tseng, C. H. Type 2 diabetes mellitus and kidney cancer risk: a retrospective cohort analysis of the National Health Insurance. PLoS One 10, e0142480 (2015).
pubmed: 26559055 pmcid: 4641625 doi: 10.1371/journal.pone.0142480
Lindblad, P. et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 42, 107–112 (1999).
pubmed: 10027588 doi: 10.1007/s001250051122
Ballotari, P. et al. Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy. BMC Cancer 17, 703 (2017).
pubmed: 29070034 pmcid: 5657107 doi: 10.1186/s12885-017-3696-4
Tseng, C. H. Use of metformin and risk of kidney cancer in patients with type 2 diabetes. Eur. J. Cancer 52, 19–25 (2016).
pubmed: 26630530 doi: 10.1016/j.ejca.2015.09.027
Wei Lai, S. et al. Kidney cancer and diabetes mellitus: a population-based case-control study in Taiwan. Ann. Acad. Med. Singap. 42, 120–124 (2013).
doi: 10.47102/annals-acadmedsg.V42N3p120
Chen, L. et al. The impact of diabetes mellitus on renal cell carcinoma prognosis: a meta-analysis of cohort studies. Medicine 94, e1055 (2015).
pubmed: 26131819 pmcid: 4504607 doi: 10.1097/MD.0000000000001055
Li, Y., Hu, L., Xia, Q., Yuan, Y. & Mi, Y. The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis. Int. Urol. Nephrol. 49, 975–981 (2017).
pubmed: 28271326 pmcid: 5443884 doi: 10.1007/s11255-017-1548-4
Nayan, M. et al. Diabetes and kidney cancer survival in patients undergoing nephrectomy: a Canadian multi-center, propensity score analysis. Urol. Oncol. Semin. Orig. Investig. 37, 576.e11–576.e16 (2019).
Antonelli, A. et al. Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: a single-center retrospective study. Urol. Oncol. Semin. Orig. Investig. 31, 1310–1315 (2013).
Ha, Y. S. et al. Multi-institutional analysis of localized renal cell carcinoma that demonstrates the impact of diabetic status on prognosis after nephrectomy. Ann. Surg. Oncol. 20, 3662–3668 (2013).
pubmed: 23907313 doi: 10.1245/s10434-013-3147-7
Psutka, S. P. et al. Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma. J. Urol. 192, 1620–1627 (2014).
pubmed: 24931804 doi: 10.1016/j.juro.2014.06.014
Lee, H. et al. Diabetes mellitus as an independent predictor of survival of patients surgically treated for renal cell carcinoma: a propensity score matching study. J. Urol. 194, 1554–1560 (2015).
pubmed: 26066406 doi: 10.1016/j.juro.2015.05.097
Süer, E., Öztürk, E., Gülpinar, Ö., Kayiş, A. & Baltaci, S. Effect of type 2 diabetes mellitus on prognosis of nonmetastatic renal cell cancer. Korean J. Urol. 54, 499–503 (2013).
pubmed: 23956823 pmcid: 3742900 doi: 10.4111/kju.2013.54.8.499
Lee, S., Hong, S. K., Kwak, C., Kim, H. H. & Lee, S. E. Prognostic significance of diabetes mellitus in localized renal cell carcinoma. Jpn. J. Clin. Oncol. 42, 318–324 (2012).
pubmed: 22389274 doi: 10.1093/jjco/hys018
Nayan, M. et al. Diabetes and kidney cancer outcomes: a propensity score analysis. Endocrine 55, 470–477 (2017).
pubmed: 27815768 doi: 10.1007/s12020-016-1149-5
Yang, H. et al. Pre-existing type 2 diabetes is an adverse prognostic factor in patients with renal cell carcinoma. J. Diabetes 11, 993–1001 (2019).
pubmed: 31141620 doi: 10.1111/1753-0407.12957
Zhang, C. et al. Association of dyslipidemia with renal cell carcinoma: a 1:2 matched case-control study. PLoS One 8, e59796 (2013).
pubmed: 23536888 pmcid: 3607555 doi: 10.1371/journal.pone.0059796
Bao, C. et al. Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis. J. Diabetes Complicat. 27, 357–364 (2013).
doi: 10.1016/j.jdiacomp.2013.01.004
Pottegård, A., Clark, P., Friis, S., Hallas, J. & Lund, L. Long-term use of statins and risk of renal cell carcinoma: a population-based case-control study. Eur. Urol. 69, 877–882 (2016).
pubmed: 26603781 doi: 10.1016/j.eururo.2015.10.020
Khurana, V., Caldito, G. & Ankem, M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology 71, 118–122 (2008).
pubmed: 18242378 doi: 10.1016/j.urology.2007.08.039
Zhang, G. M. et al. Prevalence of dyslipidaemia in patients with renal cell carcinoma: a case-control study in China. BJU Int 113, E75–E81 (2014).
pubmed: 24274674 doi: 10.1111/bju.12581
Liu, W., Choueiri, T. K. & Cho, E. Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. Cancer 118, 797–803 (2012).
pubmed: 21751202 doi: 10.1002/cncr.26338
Ohno, Y. et al. Clinical implications of preoperative serum total cholesterol in patients with clear cell renal cell carcinoma. Urology 83, 154–158 (2014).
pubmed: 24149106 doi: 10.1016/j.urology.2013.08.052
Lee, H. et al. Preoperative cholesterol level is associated with worse pathological outcomes and postoperative survival in localized renal cell carcinoma patients: a propensity score–matched study. Clin. Genitourin. Cancer 15, e935–e941 (2017).
pubmed: 28558989 doi: 10.1016/j.clgc.2017.05.008
Kang, H. W. et al. Low preoperative serum cholesterol level is associated with aggressive pathologic features and poor cancer-specific survival in patients with surgically treated renal cell carcinoma. Int. J. Clin. Oncol. 23, 142–150 (2018).
pubmed: 28791497 doi: 10.1007/s10147-017-1172-4
De Martino, M. et al. Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC). BJU Int. 115, 397–404 (2015).
pubmed: 24698164 doi: 10.1111/bju.12767
CHOI, S.-K. et al. Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy. Mol. Clin. Oncol. 1, 365–368 (2013).
pubmed: 24649176 doi: 10.3892/mco.2012.55
Hamilton, R. J. et al. The association between statin medication and progression after surgery for localized renal cell carcinoma. J. Urol. 191, 914–919 (2014).
pubmed: 24291547 doi: 10.1016/j.juro.2013.10.141
Krane, L. S., Sandberg, J. M., Rague, J. T. & Hemal, A. K. Do statin medications impact renal functional or oncologic outcomes for robot-assisted partial nephrectomy? J. Endourol. 28, 1308–1312 (2014).
pubmed: 24934083 doi: 10.1089/end.2014.0276
Kaffenberger, S. D. et al. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol. Oncol. Semin. Orig. Investig. 33, 21.e11–21.e17 (2015).
Viers, B. R. et al. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. Urol. Oncol. Semin. Orig. Investig. 33, 388.e11–388.e18 (2015).
Haddad, A. Q. et al. Statin use and serum lipid levels are associated with survival outcomes after surgery for renal cell carcinoma. Urology 86, 1146–1152 (2015).
pubmed: 26416007 doi: 10.1016/j.urology.2015.09.015
Lee, C. K. et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin. Cancer Res. 18, 3188–3196 (2012).
pubmed: 22472176 doi: 10.1158/1078-0432.CCR-11-3137
Nayan, M. et al. Statin use and kidney cancer outcomes: a propensity score analysis. Urol. Oncol. Semin. Orig. Investig. 34, 487.e1–487.e6 (2016).
Nielsen, S. F., Nordestgaard, B. G. & Bojesen, S. E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367, 1792–1802 (2012).
pubmed: 23134381 doi: 10.1056/NEJMoa1201735
Nayan, M. et al. Statin use and kidney cancer survival outcomes: a systematic review and meta-analysis. Cancer Treat. Rev. 52, 105–116 (2017).
pubmed: 27992843 doi: 10.1016/j.ctrv.2016.11.009
Kriegmair, M. C. et al. Metabolic syndrome negatively impacts the outcome of localized renal cell carcinoma. Horm. Cancer 8, 127–134 (2017).
pubmed: 28247362 pmcid: 10355923 doi: 10.1007/s12672-017-0289-2
Bulut, S. et al. Metabolic syndrome prevalence in renal cell cancer patients. Asian Pac. J. Cancer Prev. 15, 7925–7928 (2014).
pubmed: 25292088 doi: 10.7314/APJCP.2014.15.18.7925
Eskelinen, T. J., Kotsar, A., Tammela, T. L. J. & Murtola, T. J. Components of metabolic syndrome and prognosis of renal cell cancer. Scand. J. Urol. 51, 435–441 (2017).
pubmed: 28743221 doi: 10.1080/21681805.2017.1352616
Bergström, A. et al. Occupational physical activity and renal cell cancer: a nationwide cohort study in Sweden. Int. J. Cancer 83, 186–191 (1999).
pubmed: 10471525 doi: 10.1002/(SICI)1097-0215(19991008)83:2<186::AID-IJC7>3.0.CO;2-6
Bergström, A. et al. Physical activity and risk of renal cell cancer. Int. J. Cancer 92, 155–157 (2001).
pubmed: 11279620 doi: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1162>3.0.CO;2-S
Ihira, H. et al. Physical activity and subsequent risk of kidney, bladder and upper urinary tract cancer in the Japanese population: the Japan Public Health Centre-based Prospective Study. Br. J. Cancer 120, 571–574 (2019).
pubmed: 30745583 pmcid: 6461777 doi: 10.1038/s41416-019-0392-y
Mahabir, S. et al. Physical activity and renal cell cancer risk in a cohort of male smokers. Int. J. Cancer 108, 600–605 (2004).
pubmed: 14696127 doi: 10.1002/ijc.11580
Moore, S. C. et al. Physical activity during adulthood and adolescence in relation to renal cell cancer. Am. J. Epidemiol. 168, 149–157 (2008).
pubmed: 18468990 pmcid: 2878095 doi: 10.1093/aje/kwn102
Williams, P. T. Reduced risk of incident kidney cancer from walking and running. Med. Sci. Sports Exerc. 46, 312–317 (2014).
pubmed: 23863620 pmcid: 4067489 doi: 10.1249/MSS.0b013e3182a4e89c
Arem, H. et al. Physical activity and cancer-specific mortality in the NIH-AARP diet and health study cohort. Int. J. Cancer 135, 423–431 (2014).
pubmed: 24311115 doi: 10.1002/ijc.28659
Schmid, D., Matthews, C. E. & Leitzmann, M. F. Physical activity and sedentary behavior in relation to mortality among renal cell cancer survivors. PLoS One 13, e0198995 (2018).
pubmed: 29894512 pmcid: 5997343 doi: 10.1371/journal.pone.0198995
Liss, M. et al. Physical activity decreases kidney cancer mortality. Curr. Urol. 10, 193–198 (2017).
pubmed: 29234262 pmcid: 5704719 doi: 10.1159/000447180
Nicodemus, K. K., Sweeney, C. & Folsom, A. R. Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women. Int. J. Cancer 108, 115–121 (2004).
pubmed: 14618625 doi: 10.1002/ijc.11532
Cannioto, R. et al. The association of lifetime physical inactivity with bladder and renal cancer risk: a hospital-based case-control analysis. Cancer Epidemiol. 49, 24–29 (2017).
pubmed: 28528291 pmcid: 5544555 doi: 10.1016/j.canep.2017.04.017
Tavani, A. et al. Lifetime physical activity and the risk of renal cell cancer. Int. J. Cancer 120, 1977–1980 (2007).
pubmed: 17266025 doi: 10.1002/ijc.22438
Mellemgaard, A. et al. International renal‐cell cancer study. III. Role of weight, height, physical activity, and use of amphetamines. Int. J. Cancer 60, 350–354 (1995).
pubmed: 7829243 doi: 10.1002/ijc.2910600313
Goodman, M. T., Morgenstern, H. & Wynder, E. L. A case-control study of factors affecting the development of renal cell cancer. Am. J. Epidemiol. 124, 926–941 (1986).
pubmed: 3776975 doi: 10.1093/oxfordjournals.aje.a114482
Parent, M. É. et al. Occupational and recreational physical activity during adult life and the risk of cancer among men. Cancer Epidemiol. 35, 151–159 (2011).
pubmed: 21030330 doi: 10.1016/j.canep.2010.09.004
Chiu, B. C. H. et al. Body mass index, physical activity, and risk of renal cell carcinoma. Int. J. Obes. 30, 940–947 (2006).
doi: 10.1038/sj.ijo.0803231
Pan, S. Y. et al. Obesity, high energy intake, lack of physical activity, and the risk of kidney cancer. Cancer Epidemiol. Biomark. Prev. 15, 2453–2460 (2006).
doi: 10.1158/1055-9965.EPI-06-0616
Brownson, R. C., Chang, J. C., Davis, J. R. & Smith, C. A. Physical activity on the job and cancer in Missouri. Am. J. Public Health 81, 639–642 (1991).
pubmed: 2014869 pmcid: 1405078 doi: 10.2105/AJPH.81.5.639
Mctiernan, A. et al. Physical activity in cancer prevention and survival: a systematic review. Med. Sci. Sports Exerc. 51, 1252–1261 (2019).
pubmed: 31095082 pmcid: 6527123 doi: 10.1249/MSS.0000000000001937
Behrens, G. & Leitzmann, M. F. The association between physical activity and renal cancer: Systematic review and meta-analysis. Br. J. Cancer 108, 798–811 (2013).
pubmed: 23412105 pmcid: 3590672 doi: 10.1038/bjc.2013.37
World Cancer Research Fund & American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective (AICR, 2007)
Brock, K. E. et al. Fruit, vegetables, fibre and micronutrients and risk of US renal cell carcinoma. Br. J. Nutr. 108, 1077–1085 (2012).
pubmed: 22186835 doi: 10.1017/S0007114511006489
Daniel, C. R. et al. Intake of fiber and fiber-rich plant foods is associated with a lower risk of renal cell carcinoma in a large US cohort. Am. J. Clin. Nutr. 97, 1036–1043 (2013).
pubmed: 23515007 pmcid: 3628376 doi: 10.3945/ajcn.112.045351
Jung, E. L. et al. Intakes of fruit, vegetables, and carotenoids and renal cell cancer risk: a pooled analysis of 13 prospective studies. Cancer Epidemiol. Biomark. Prev. 18, 1730–1739 (2009).
doi: 10.1158/1055-9965.EPI-09-0045
Bertoia, M. et al. No association between fruit, vegetables, antioxidant nutrients and risk of renal cell carcinoma. Int. J. Cancer 126, 1504–1512 (2010).
pubmed: 19685494 pmcid: 2811212 doi: 10.1002/ijc.24829
Bravi, F. et al. Food groups and renal cell carcinoma: a case-control study from Italy. Int. J. Cancer 120, 681–685 (2007).
pubmed: 17058282 doi: 10.1002/ijc.22225
Weikert, S. et al. Fruits and vegetables and renal cell carcinoma: findings from the European prospective investigation into cancer and nutrition (EPIC). Int. J. Cancer 118, 3133–3139 (2006).
pubmed: 16425278 doi: 10.1002/ijc.21765
Handa, K. & Kreiger, N. Diet patterns and the risk of renal cell carcinoma. Public Health Nutr. 5, 757–767 (2002).
pubmed: 12570884 doi: 10.1079/PHN2002347
De Stefani, E. et al. Meat intake, ‘mate’ drinking and renal cell cancer in Uruguay: a case-control study. Br. J. Cancer 78, 1239–1243 (1998).
pubmed: 9820187 pmcid: 2062999 doi: 10.1038/bjc.1998.661
Dolwick Grieb, S. M. et al. Food groups and renal cell carcinoma: results from a case-control study. J. Am. Diet. Assoc. 109, 656–667 (2009).
doi: 10.1016/j.jada.2008.12.020
Lee, J. E. et al. Intakes of fruits, vegetables, vitamins A, C, and E, and carotenoids and risk of renal cell cancer. Cancer Epidemiol. Biomark. Prev. 15, 2445–2452 (2006).
doi: 10.1158/1055-9965.EPI-06-0553
Daniel, C. R. et al. Meat-cooking mutagens and risk of renal cell carcinoma. Br. J. Cancer 105, 1096–1104 (2011).
pubmed: 21897389 pmcid: 3185955 doi: 10.1038/bjc.2011.343
Talamini, R. et al. A case-control study of risk factor for renal cell cancer in northern Italy. Cancer Causes Control. 1, 125–132 (1990).
pubmed: 2102282 doi: 10.1007/BF00053163
Wolk, A. et al. International renal cell cancer study. VII. Role of diet. Int. J. Cancer 65, 67–73 (1996).
pubmed: 8543399 doi: 10.1002/(SICI)1097-0215(19960103)65:1<67::AID-IJC12>3.0.CO;2-F
Mellemgaard, A., McLaughlin, J. K., Overvad, K. & Olsen, J. H. Dietary risk factors for renal cell carcinoma in Denmark. Eur. J. Cancer 32, 673–682 (1996).
doi: 10.1016/0959-8049(95)00633-8
Huang, T. B. et al. Dietary fiber intake and risk of renal cell carcinoma: evidence from a meta-analysis. Med. Oncol. 31, 125 (2014).
pubmed: 25038944 doi: 10.1007/s12032-014-0125-2
Zhang, S., Jia, Z., Yan, Z. & Yang, J. Consumption of fruits and vegetables and risk of renal cell carcinoma: a meta-analysis of observational studies. Oncotarget 8, 27892–27903 (2017).
pubmed: 28427188 pmcid: 5438616 doi: 10.18632/oncotarget.15841
Daniel, C. R. et al. Large prospective investigation of meat intake, related mutagens, and risk of renal cell carcinoma. Am. J. Clin. Nutr. 95, 155–162 (2012).
pubmed: 22170360 doi: 10.3945/ajcn.111.019364
Faramawi, M. F., Johnson, E., Fry, M. W., Sall, M. & Yi, Z. Consumption of different types of meat and the risk of renal cancer: meta-analysis of case-control studies. Cancer Causes Control. 18, 125–133 (2007).
pubmed: 17242980 doi: 10.1007/s10552-006-0104-9
Lee, J. E. et al. Fat, protein, and meat consumption and renal cell cancer risk: a pooled analysis of 13 prospective studies. J. Natl Cancer Inst. 100, 1695–1706 (2008).
pubmed: 19033572 pmcid: 2727138 doi: 10.1093/jnci/djn386
Rohrmann, S. et al. Meat and fish consumption and the risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Int. J. Cancer 136, E423–E431 (2015).
pubmed: 25258006 doi: 10.1002/ijc.29236
Wijarnpreecha, K., Thongprayoon, C., Thamcharoen, N., Panjawatanan, P. & Cheungpasitporn, W. Association between coffee consumption and risk of renal cell carcinoma: a meta-analysis. Intern. Med. J. 47, 1422–1432 (2017).
pubmed: 28892303 doi: 10.1111/imj.13621
Shen, C., Huang, Y., Yi, S., Fang, Z. & Li, L. Association of vitamin E intake with reduced risk of kidney cancer: a meta-analysis of observational studies. Med. Sci. Monit. 21, 3420–3426 (2015).
pubmed: 26547129 pmcid: 4644018 doi: 10.12659/MSM.896018
Melkonian, S. C. et al. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer 122, 108–115 (2016).
pubmed: 26551148 doi: 10.1002/cncr.29543
Parker, A. S., Cerhan, J. R., Lynch, C. F., Ershow, A. G. & Cantor, K. P. Gender, alcohol consumption, and renal cell carcinoma. Am. J. Epidemiol. 155, 455–462 (2002).
pubmed: 11867357 doi: 10.1093/aje/155.5.455
Song, D. Y., Song, S., Song, Y. & Lee, J. E. Alcohol intake and renal cell cancer risk: a meta-analysis. Br. J. Cancer 106, 1881–1890 (2012).
pubmed: 22516951 pmcid: 3364130 doi: 10.1038/bjc.2012.136
Lee, J. E. et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J. Natl Cancer Inst. 99, 801–810 (2007).
pubmed: 17505075 doi: 10.1093/jnci/djk181
Lew, J. Q., Chow, W. H., Hollenbeck, A. R., Schatzkin, A. & Park, Y. Alcohol consumption and risk of renal cell cancer: the NIH-AARP diet and health study. Br. J. Cancer 104, 537–541 (2011).
pubmed: 21245859 pmcid: 3049576 doi: 10.1038/sj.bjc.6606089
Bellocco, R. et al. Alcohol drinking and risk of renal cell carcinoma: results of a meta-analysis. Ann. Oncol. 23, 2235–2244 (2012).
pubmed: 22398178 doi: 10.1093/annonc/mds022
Karami, S., Daugherty, S. E. & Purdue, M. P. A prospective study of alcohol consumption and renal cell carcinoma risk. Int. J. Cancer 137, 238–242 (2015).
pubmed: 25431248 doi: 10.1002/ijc.29359
IWH. Primary, secondary and tertiary prevention. IWH https://www.iwh.on.ca/what-researchers-mean-by/primary-secondary-and-tertiary-prevention (2015).
Tahbaz, R., Schmid, M. & Merseburger, A. S. Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr. Opin. Urol. 28, 62–79 (2018).
pubmed: 29059103 doi: 10.1097/MOU.0000000000000454
Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 67, 913–924 (2015).
pubmed: 25616710 doi: 10.1016/j.eururo.2015.01.005
Ljungberg, B. et al. European Association of Urology Guidelines on renal cell carcinoma: the 2022 update. Eur. Urol. https://doi.org/10.1016/J.EURURO.2022.03.006 (2022).
doi: 10.1016/J.EURURO.2022.03.006 pubmed: 36526491
Wozniak, M. B. et al. Alcohol consumption and the risk of renal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int. J. Cancer 137, 1953–1966 (2015).
pubmed: 25866035 doi: 10.1002/ijc.29559
Xu, X., Zhu, Y., Zheng, X. & Xie, L. Does beer, wine or liquor consumption correlate with the risk of renal cell carcinoma? A dose-response meta-analysis of prospective cohort studies. Oncotarget 6, 13347–13358 (2015).
pubmed: 25965820 pmcid: 4537019 doi: 10.18632/oncotarget.3749
Al-Bayati, O., Hasan, A., Pruthi, D., Kaushik, D. & Liss, M. A. Systematic review of modifiable risk factors for kidney cancer. Urol. Oncol. Semin. Orig. Investig. 37, 359–371 (2019).
Raffle, A. E. & Muir, J. A. Books & electronic media Screening: evidence and practice. Bulletin of the World Health Organization vol. 86 (Oxford University Press, 2008).
Bonita, R., Beaglehole, R., Kjellström, T. & Organization, W. H. Basic epidemiology. Teacher’s guide for basic epidemiology, WHO document (WHO, 2006).
Usher-Smith, J., Simmons, R. K., Rossi, S. H. & Stewart, G. D. Current evidence on screening for renal cancer. Nat. Rev. Urol. 17, 637–642 (2020).
pubmed: 32860009 pmcid: 7610655 doi: 10.1038/s41585-020-0363-3
Harrison, H. et al. Risk prediction models for kidney cancer: a systematic review. Eur. Urol. Focus. 7, 1380–1390 (2021).
pubmed: 32680829 pmcid: 8642244 doi: 10.1016/j.euf.2020.06.024
Diana, P. et al. Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group. World J. Urol. https://doi.org/10.1007/s00345-022-03993-6 (2022).
doi: 10.1007/s00345-022-03993-6 pubmed: 35980449 pmcid: 10160199
ROSE, G. Sick individuals and sick populations. Int. J. Epidemiol. 14, 32–38 (1985).
pubmed: 3872850 doi: 10.1093/ije/14.1.32
Rossi, S. H. et al. A decision analysis evaluating screening for kidney cancer using focused renal ultrasound. Eur. Urol. Focus. https://doi.org/10.1016/j.euf.2019.09.002 (2019).
doi: 10.1016/j.euf.2019.09.002 pubmed: 31530498
Roussel, E. et al. Novel imaging methods for renal mass characterization: a collaborative review. Eur. Urol. 81, 476–488 (2022).
pubmed: 35216855 pmcid: 9844544 doi: 10.1016/j.eururo.2022.01.040
Rossi, S. H. et al. Meta-analysis of the prevalence of renal cancer detected by abdominal ultrasonography. Br. J. Surg. 104, 648–659 (2017).
pubmed: 28407225 doi: 10.1002/bjs.10523
Crosbie, P. A. et al. Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk. BMJ Open 10, e037075 (2020).
pubmed: 32912947 pmcid: 7485242 doi: 10.1136/bmjopen-2020-037075
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05005195 (2022).
Scelo, G. et al. KIM-1 as a blood-based marker for early detection of kidney cancer: a prospective nested case-control study. Clin. Cancer Res. 24, 5594–5601 (2018).
pubmed: 30037816 pmcid: 6239904 doi: 10.1158/1078-0432.CCR-18-1496
Usher-Smith, J. A., Sharp, S. J., Luben, R. & Griffin, S. J. Development and validation of lifestyle-based models to predict incidence of the most common potentially preventable cancers. Cancer Epidemiol. Biomark. Prev. 28, 67–75 (2019).
doi: 10.1158/1055-9965.EPI-18-0400
Harrison, H. et al. Validation and public health modelling of risk prediction models for kidney cancer using the UK Biobank. BJU Int. https://doi.org/10.1111/BJU.15598 (2021).
doi: 10.1111/BJU.15598 pubmed: 34538014
Usher-Smith, J. A. et al. External validation of risk prediction models for incident colorectal cancer using UK Biobank. Br. J. Cancer 118, 750–759 (2018).
pubmed: 29381683 pmcid: 5846069 doi: 10.1038/bjc.2017.463
Amir, E., Freedman, O. C., Seruga, B. & Evans, D. G. Assessing women at high risk of breast cancer: a review of risk assessment models. J. Natl Cancer Inst. 102, 680–691 (2010).
pubmed: 20427433 doi: 10.1093/jnci/djq088
Flitcroft, J. G. et al. Early detection of kidney cancer using urinary proteins: a truly non-invasive strategy. BJU Int. 129, 290–303 (2022).
pubmed: 34570419 doi: 10.1111/bju.15601
Scelo, G. & Larose, T. L. Epidemiology and risk factors for kidney cancer. J. Clin. Oncol. 36, 3574–3581 (2018).
pmcid: 6299342 doi: 10.1200/JCO.2018.79.1905

Auteurs

Riccardo Campi (R)

Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.
Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands.

Giacomo Rebez (G)

Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands.
Department of Urology, Cattinara Hospital, University of Trieste, Trieste, Italy.

Tobias Klatte (T)

Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands.
Department of Urology, Royal Bournemouth Hospital, Bournemouth, UK.

Eduard Roussel (E)

Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands.
Department of Urology, KU Leuven, Leuven, Belgium.

Idir Ouizad (I)

Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands.
Department of Urology, Bichat-Claude Bernard Hospital, Paris, France.

Alexander Ingels (A)

Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands.
Department of Urology, Henri Mondor Hospital, Créteil, France.

Nicola Pavan (N)

Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands.
Department of Urology, Cattinara Hospital, University of Trieste, Trieste, Italy.

Onder Kara (O)

Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands.
Faculty of Medicine, Kocaeli University, İzmit, Turkey.

Selcuk Erdem (S)

Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands.
Department of Urology, Istanbul University, Istanbul, Turkey.

Riccardo Bertolo (R)

Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands.
Urology Unit, Department of Surgery, Tor Vergata University of Rome, Rome, Italy.

Umberto Capitanio (U)

Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands.
Department of Urology, San Raffaele Scientific Institute, Milan, Italy.
Division of Experimental Oncology/Unit of Urology, IRCCS San Raffaele Hospital, Milan, Italy.

Maria Carmen Mir (MC)

Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, Netherlands. mirmare@yahoo.es.
Department of Urology, Hospital Universitario La Ribera, Valencia, Spain. mirmare@yahoo.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH